Terms: = Ovarian cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Clinical Outcome
51 results:
1. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
[TBL] [Abstract] [Full Text] [Related]
2. A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.
Devereaux KA; Steiner DF; Ho C; Gomez AJ; Gilks B; Longacre TA; Zehnder JL; Howitt BE; Suarez CJ
Int J Gynecol Pathol; 2022 Nov; 41(6):541-551. PubMed ID: 34907997
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD).
Macchia G; Jereczek-Fossa BA; Lazzari R; Cerrotta A; Deodato F; Ippolito E; Aristei C; Gambacorta MA; Scambia G; Valentini V; Ferrandina G
Int J Gynecol Cancer; 2022 Jul; 32(7):939-943. PubMed ID: 34155084
[TBL] [Abstract] [Full Text] [Related]
4. Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
Narasimhulu DM; Bews KA; Hanson KT; Chang YH; Dowdy SC; Cliby WA
Gynecol Oncol; 2020 Feb; 156(2):278-283. PubMed ID: 31785863
[TBL] [Abstract] [Full Text] [Related]
5. Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study.
Zhang H; Mao Y; Chen X; Wu G; Liu X; Zhang P; Bai Y; Lu P; Yao W; Wang Y; Yu J; Zhang G
Eur Radiol; 2019 Jul; 29(7):3358-3371. PubMed ID: 30963272
[TBL] [Abstract] [Full Text] [Related]
6. Seven Genes Based Novel Signature Predicts clinical outcome and Platinum Sensitivity of High Grade IIIc Serous ovarian Carcinoma.
Liu G; Chen L; Ren H; Liu F; Dong C; Wu A; Liu Z; Zheng Y; Cheng X; Liu L
Int J Biol Sci; 2018; 14(14):2012-2022. PubMed ID: 30585265
[No Abstract] [Full Text] [Related]
7. Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological cancers.
Nielsen B; Kleppe A; Hveem TS; Pradhan M; Syvertsen RA; Nesheim JA; Kristensen GB; Trovik J; Kerr DJ; Albregtsen F; Danielsen HE
J Natl Cancer Inst; 2018 Dec; 110(12):1400-1408. PubMed ID: 29684152
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract] [Full Text] [Related]
9. clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer.
Wei W; Li N; Sun Y; Li B; Xu L; Wu L
Oncotarget; 2017 Apr; 8(14):23862-23870. PubMed ID: 27852043
[TBL] [Abstract] [Full Text] [Related]
10. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract] [Full Text] [Related]
11. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous ovarian cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract] [Full Text] [Related]
12. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 ovarian cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank ovarian cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract] [Full Text] [Related]
13. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.
Pereira D; Assis J; Gomes M; Nogueira A; Medeiros R
Eur J Clin Pharmacol; 2016 May; 72(5):545-53. PubMed ID: 26803611
[TBL] [Abstract] [Full Text] [Related]
14. [Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Špaček J
Ceska Gynekol; 2015 Dec; 80(6):405-13. PubMed ID: 26741154
[TBL] [Abstract] [Full Text] [Related]
15. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Wong KK
Br J Cancer; 2015 Nov; 113(9):1254-8. PubMed ID: 26484411
[TBL] [Abstract] [Full Text] [Related]
16. clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
Watkins JL; Thaker PH; Nick AM; Ramondetta LM; Kumar S; Urbauer DL; Matsuo K; Squires KC; Coleman RL; Lutgendorf SK; Ramirez PT; Sood AK
Cancer; 2015 Oct; 121(19):3444-51. PubMed ID: 26301456
[TBL] [Abstract] [Full Text] [Related]
17. The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis.
Li J; Li S; Chen R; Yu H; Lu X
J Ovarian Res; 2015 Aug; 8():54. PubMed ID: 26242216
[TBL] [Abstract] [Full Text] [Related]
18. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract] [Full Text] [Related]
19. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Tran AQ; Cohen JG; Li AJ
Gynecol Oncol; 2015 Aug; 138(2):263-6. PubMed ID: 26037901
[TBL] [Abstract] [Full Text] [Related]
20. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.
Kamieniak MM; Rico D; Milne RL; Muñoz-Repeto I; Ibáñez K; Grillo MA; Domingo S; Borrego S; Cazorla A; García-Bueno JM; Hernando S; García-Donas J; Hernández-Agudo E; Y Cajal TR; Robles-Díaz L; Márquez-Rodas I; Cusidó M; Sáez R; Lacambra-Calvet C; Osorio A; Urioste M; Cigudosa JC; Paz-Ares L; Palacios J; Benítez J; García MJ
Mol Oncol; 2015 Feb; 9(2):422-36. PubMed ID: 25454820
[TBL] [Abstract] [Full Text] [Related]
[Next]
